Viglita 50mg 10pcs

Indications

When diet, exercise, and a single antidiabetic agent do not result in adequate glycemic control, Vildagliptin is used as a supplement to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. It is also used in dual combination with Metformin, a Sulphonylurea, a Thiazolidinedione, or Insulin.

Pharmacology

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is thought to work by slowing the inactivation of incretin hormones in type 2 diabetes patients. The intestine releases incretin hormones throughout the day, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and levels rise in response to a meal.

Dosage & Administration

The recommended dose of Vildagliptin is-

• 50 mg or 100 mg daily for monotherapy.
• 50 mg twice daily (morning and evening) when used in dual combination with Metformin or a Thiazolidinedione;
• 50 mg once daily in the morning when used in dual combination with a Sulphonylurea.
• Vildagliptin may be taken with or without a meal. No dosage adjustment is required in the elderly, or in patients with mild renal impairment.
• Pediatric use: Vildagliptin is not recommended in patients 18 years of a

Interaction

There were no interactions with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan, or simvastatin in pharmacokinetic studies. Certain active substances, such as thiazides, corticosteroids, thyroid products, and sympathomimetics, may reduce Vildagliptin’s glucose-lowering effect, as they do with other oral antidiabetic medicinal products.

Contraindications

Vildagliptin is contraindicated in patients with:

• Hypersensitivity to the active substance or to any of the excipients
• Patients with moderate to severe renalImpairment
• Patients with Hepatic Impairment: patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotrasferase (AST) >3 times the upper limit of normal (ULN).
• Patients with type 1 diabetes

Side Effect

The majority of side effects were mild and transient, necessitating no treatment interruptions. There is a rare case of hepatic dysfunction. Clinical trials lasting up to and including 2 years found no additional safety signals or unexpected risks when this combination was used.

Pregnancy & Lactation

Vildagliptin is not recommended for use during pregnancy. During lactation, Vildagliptin should be avoided.

Precautions & Warnings

Due to a lack of clinical experience, patients aged 75 and older should be treated with caution. LFTs should be checked before starting Vildagliptin, at three-monthly intervals for the first year, and then on a regular basis after that. If transaminase levels are elevated, patients should have a second liver function test to confirm the result and be followed up on.

Storage Conditions

Keep the temperature below 30?C and away from light and moisture. Keep out of children’s reach.